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in order to survive and propagate, rNA viruses must achieve 
a balance between the capacity for adaptation to new 
environmental conditions or host cells with the need to 
maintain an intact and replication competent genome. Several 
virus families in the order Nidovirales, such as the coronaviruses 
(Covs) must achieve these objectives with the largest and 
most complex replicating rNA genomes known, up to 32 kb 
of positive-sense rNA. The Covs encode sixteen nonstructural 
proteins (nsp 1–16) with known or predicted rNA synthesis and 
modification activities, and it has been proposed that they are 
also responsible for the evolution of large genomes. The Covs, 
including murine hepatitis virus (MHv) and SArS-Cov, encode 
a 3'-to-5' exoribonuclease activity (exoN) in nsp14. Genetic 
inactivation of exoN activity in engineered SArS-Cov and MHv 
genomes by alanine substitution at conserved De-D-D active 
site residues results in viable mutants that demonstrate 15- to 
20-fold increases in mutation rates, up to 18 times greater than 
those tolerated for fidelity mutants of other rNA viruses. Thus 
nsp14-exoN is essential for replication fidelity, and likely serves 
either as a direct mediator or regulator of a more complex rNA 
proofreading machine, a process previously unprecedented 
in rNA virus biology. elucidation of the mechanisms of nsp14-
mediated proofreading will have major implications for our 
understanding of the evolution of rNA viruses, and also will 
provide a robust model to investigate the balance between 
fidelity, diversity and pathogenesis. The discovery of a protein 
distinct from a viral rdrp that regulates replication fidelity 
also raises the possibility that rNA genome replication fidelity 
may be adaptable to differing replication environments and 
selective pressures, rather than being a fixed determinant.
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Introduction
Coronaviruses (CoVs) are a family of RNA viruses that cause 
significant diseases in humans such as severe acute respiratory 
syndrome (SARS) and other respiratory infections, as well as a 
variety of respiratory, gastrointestinal and other infections in an 
increasingly large variety of mammals and birds. The capacity 
CoVs possess for trans-species movement and adaptation, long 
recognized in the laboratory,1 was confirmed in nature by the 
recent emergence of several animal coronavirus pathogens of 
domesticated animals and SARS-CoV. Data on the latter emer-
gence event indicated that SARS likely resulted from human 
infection and adaptation by a Bat SARS-like CoV.2,3 Finally, 
the “post-SARS” identification and analysis of a vast diversity 
of newly identified coronaviruses across bat species,4 along with 
the successful synthetic resurrection of a Bat SARS-like CoV,5 
suggests that many, if not all, mammalian CoVs may originate 
from bats.6 However, the mechanisms of CoV host species move-
ment and adaptation for replication and pathogenesis are poorly 
understood. This review will discuss the role of RNA replica-
tion fidelity in RNA virus replication and pathogenesis, and will 
focus on a novel exoribonuclease universally encoded within CoV 
genomes that likely mediates RNA-dependent RNA proofread-
ing during virus replication.7,8
Impact of Replication Fidelity and Diversity  
on RNA Virus Adaptation and Pathogenesis
Due to high error rates of RNA replication, RNA viruses exist 
as quasispecies, defined as “ensembles of related genotypes”.9,10 
There is evidence that evolutionary selection targets RNA 
virus quasispecies populations rather than individual vari-
ants,11,12 and that cooperative interactions between variants 
influences RNA virus pathogenesis. Cell culture passage of a 
mumps vaccine strain associated with meningitis resulted in 
reduced neurovirulence that correlated with heterogeneity 
at specific positions in multiple viral genes.13 For West Nile 
©2011 Landes Bioscience.
Do not distribute.
www.landesbioscience.com rNA Biology 271
 review review
Coronavirus Transcription, Replication 
and Recombination
CoVs are enveloped viruses that have positive-sense, non-seg-
mented RNA genomes 27–32 kb in length. The basic gene 
organization and replication is similar for all CoVs and is illus-
trated for SARS-CoV (Fig. 1). Gene 1 encodes all predicted 
replicase/transcriptase proteins, which are translated from 
input genome RNA (RNA1). Genes 2–9 encode structural and 
accessory proteins, which are translated from separate subge-
nomic (sg) mRNAs.19-22 CoVs, as members of the Nidovirales 
order, generate not only new genome RNA, but also a 3'-nested 
set (Nido = nest) of subgenomic mRNAs (sgRNAs). Along with 
a portion of the 3' genome sequence, each CoV sgRNA also 
contains the first approximately 70 nt of the 5' leader sequence 
(Fig. 2). Coronavirus RNA synthesis can be conceptualized as 
involving two stages: genome replication and subgenomic RNA 
transcription. In genome replication, the plus-strand genome 
RNA is transcribed into a full-length minus-strand template 
RNA, and then significantly more plus-strand genome RNAs 
are synthesized from that minus-strand template. In subge-
nomic RNA transcription, 3'-nested subgenomic RNAs are 
transcribed to serve as templates for translation of the viral 
structural and accessory proteins. This stage of viral RNA 
synthesis involves a discontinuous RNA transcription model 
termed transcription attenuation during negative strand RNA 
synthesis.21-25 During negative strand synthesis, the viral RdRp 
recognizes virus-specific conserved sequences termed transcrip-
tional regulatory sequences (TRSs), located just upstream of 
each subgenomic ORF. At these points, the polymerase either 
reads through to the next TRS or dissociates from the tem-
plate strand, then re-associates with the leader TRS, located in 
the 5' UTR, and completes synthesis of a set of subgenomic 
length negative strand RNA containing an antileader RNA 
sequence and equivalent in size to each viral mRNA. These 
subgenomic negative strand RNAs then function as the prin-
cipal templates for the production of subgenomic mRNAs 
virus, increased genetic heterogeneity after mosquito cell pas-
sage correlated with growth fitness in those cells.14 Another 
study provided evidence suggesting that innate immunity can 
limit poliovirus pathogenesis by restricting viral diversity dur-
ing transit to vulnerable tissues such as brain.15 Despite the 
clear linkage between replication fidelity and pathogenesis, 
and although numerous studies support high mutation rates 
of RNA viruses, the range of genetic variability tolerated by 
specific viruses is not well understood. A four-fold increase in 
mutation frequency of poliovirus through chemical mutagen-
esis reduced infectivity by 95%.16 In contrast, a 2-to-3-fold 
decrease in mutation frequency (3Dpol-G64S) reduced the 
capacity of the mutant poliovirus to compete with WT virus in 
direct competition assays in culture and in mice and resulted 
in highly attenuated viruses with restricted tissue tropism in 
mice.12,15,17 Vesicular stomatitis virus (VSV) likely has a narrow 
tolerance for alteration in replication fidelity, based on the find-
ing that mutations from chemical mutagenesis at two defined 
single-nucleotide positions in VSV genomes could be only 
moderately increased (2–3-fold) without abolishing infectiv-
ity.18 Underscoring the contribution of diversity to pathogen-
esis, modulation of replication fidelity is a new and promising 
approach for engineering live-attenuated RNA virus vaccines. 
Poliovirus RdRp mutants with restricted genetic diversity elicit 
a protective immune response in mice comparable to the Sabin 
type 1 vaccine strain but have superior genetic stability since 
increased replication fidelity minimizes reversion to virulence.17 
Although constitutively low replication fidelity (m = 10-4 to 
10-5 substitutions per nt per round of replication) is thought 
to be a key determinant of RNA virus quasispecies diversity, 
adaptation and virulence, the tolerated range of increased or 
decreased fidelity has appeared to be constrained to less than 
4-fold. This is in sharp contrast to DNA genomes of bacteria 
such as E. coli that may have profoundly greater fidelity (10-9 to 
10-11 substitutions per gene per round of replication) but may 
tolerate up to 1,000 fold differences in replication fidelity in 
viable mutator phenotype bacteria.
Figure 1. SArS-Cov genome organization, reverse genetics and nsp14-exoN motifs and mutations. (A) SArS-Cov genome. ~29.7 kb single-strand (+) 
rNA. OrF1ab replicase gene is shown in gray with nonstructural protein domains (nsp) 1–16 indicated. Putative rNA synthesis proteins are indicated 
as in text. Nsp14/exoN is yellow. (B) Schematic shows nsp14 with three exoN motifs in red and zinc finger motif hatched. (C) Alignment and MHv and 
SArS-Cov nsp14 motifs, with conserved active site residues in red. Location of alanine substitutions are indicated, with resulting mutant.
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is supported by studies showing targeted recombination between 
specially designed mutant subgenomic mRNAs and genome 
length templates.37,38 Viable mutant CoVs can be recovered with 
artificial TRS sequences, as long as the leader and intergenic TRS 
sequences match. Further, these artificial TRS sequence viruses 
prevent recombination with virus containing the native TRS 
sequences.27 These factors combine to allow for the predicted 
rapid evolution of structural genes, especially within the Spike 
gene, which undergoes high positive selective pressure during 
emergence and host-shift events.39-42
Coronavirus Replicase Protein Expression  
and Functions
The viral proteins responsible for CoV replication, transcription 
and recombination are encoded as protein domains of the larg-
est known RNA virus polyproteins (Fig. 1). The CoV ORF1a 
and fusion ORF1ab replicase polyproteins are expressed from the 
~20 kb gene 1 on the input genome RNA and subsequently are 
processed by viral proteinases to yield 16 mature nonstructural 
proteins (nsps 1–16), as well as several intermediate precursors, 
as recently reviewed in reference 43. Nsps 4–16 are significantly 
conserved in all known CoVs and have been experimentally 
demonstrated or predicted to be critical enzymes in CoV RNA 
synthesis and modification, including: nsp7-nsp8, hexadecamer 
with putative processivity activities; nsp8, primase;44 nsp12, 
RNA-dependent RNA polymerase (RdRp);45 nsp13, RNA 
helicase-ATPase (Hel);46,47 nsp14, exoribonuclease (ExoN),48 
and methyltransferase;49 nsp15 endoribonuclease (EndoU);50-
54 and nsp16, RNA 2'-O-methyltransferase (MT).55,56 In addi-
tion, multiple nsps may be required for certain functions in 
RNA synthesis, as it has recently been shown that interactions of 
nsps 10, 14 and 16 are required for methyl transferase activity.57 
Remarkably, viruses with mutations that ablate the 2'-O-methyl 
transferase activity encoded in nsp16 are highly sensitive to the 
activity of the interferon stimulated gene IFIT-2, which likely 
inhibits the translation of RNA molecules lacking 2'-O-methyl 
modifications.58
that are 3'-coterminal, and that all possess an ~70 nt 5' leader 
sequence. Because of this transcription mechanism, alterations 
in TRS sequences can influence viral replication efficiency.26,27 
Importantly, the primary TRS sequence seems less important, 
as recombinant viruses engineered to encode completely new 
TRS networks are viable, suggesting that regulatory sequences 
flanking the TRS elements are critical regulators of subgenomic 
transcription.27 Recently, Wu and Brian have shown that arti-
ficial, marked positive-sense subgenomic mRNAs can function 
as templates for minus strand synthesis and likely contribute to 
amplifying the amounts of plus-strand sg mRNAs synthesized 
during infection. Moreover, mRNAs also can serve as tem-
plates for the synthesis of smaller sg mRNAs by recognition of 
internal TRS elements as well.28 The specific mechanism that 
confers the capacity of the polymerase to dissociate and reas-
sociate is not well understood, but is thought to be mediated by 
complementary binding of the anti-TRS on the nascent minus 
strand with the leader template TRS on the plus strand.29-31 
As rare misaligned leader-body junctions are occasionally seen 
during transcription,21,22 it is possible that one or more unique 
RNA modifying activities, like nsp14 ExoN which encodes a 
3'-5' exonuclease activity (see below), may process the ends of 
incomplete negative strand RNAs to promote base-pairing and 
the priming of antileader RNA synthesis.
Coronaviruses and Recombination
Recombination has shaped the population genetic structure of 
coronaviruses, promoting cross-species transmission and patho-
genesis while complicating vaccine design.5,27,32 Coronaviruses 
are quite capable of mediating homologous RNA recombination, 
with rates approaching 20% during mixed infection of closely 
related strains in the same group.33-35 This high recombination 
frequency is likely due to the large size of the genome, paired 
with replication machinery that is already equipped to dissociate 
and reassociate from the template RNA (site-assisted copy choice 
recombination), as well as the availability of full-length and 
subgenomic-length strands for template switching.36 This view 
Figure 2. Coronavirus subgenomic (sg) mrNA synthesis. See text for discussion. red arrows show direction of rNA synthesis.
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hinting at less robust interactions with nsp5 and ORF3b. Clearly, 
additional biochemical and genetic studies are needed to identify 
the nsp14 viral and cellular protein interactome.66,67
Nsp14-ExoN is Required for Replication Fidelity
Substitution of alanine at DE Motif I of either MHV (M-ExoN) 
or SARS-CoV (S-ExoN) allows recovery of viable mutants with 
modest replication defects of less than 1 log in peak titer com-
pared to wild type, indicating that functional ExoN activity is 
not required for CoV replication in culture. Sequencing revealed 
12- to 20-fold increases in mutation frequency and up to 14-fold 
increase in mutation rate than comparably isolated and sequenced 
wildtype MHV or SARS-CoV (Fig. 3).7,8 Thus, both M-ExoN 
and S-ExoN have similar high-level mutator phenotypes, from 5 
to 20 times greater than that seen with other RNA viruses with 
described fidelity defects, representing the highest-level muta-
tor phenotype of any RNA virus. The mutator phenotype of 
M-ExoN was maintained over at least 17 passages, as was the 
stable replication defect. The mutations accumulated in a linear 
manner over passage consistent with a stable mutator phenotype. 
Interestingly, M-ExoN has an estimated mutation rate similar to 
other known wt RNA viruses, while wt MHV in fact had a muta-
tion rate 15-fold less than other RNA viruses, suggesting that 
ExoN confers very high replication fidelity on CoV genome rep-
lication. This result was consistent with predictions that ExoN 
may be required for the stability of large RNA genomes.55,59 To 
test whether these findings could be applied across divergent 
CoVs, the studies also were performed with S-ExoN in Vero 
cells with very limited replication cycles and complete genome 
Coronavirus nsp14: A Multifunctional Protein with 
Exoribonuclease and Methyltransferase Activity
At 27 to 32 kb, the positive-sense RNA genomes of CoVs (Fig. 
1) are the largest known RNA genomes59,60 at up to twice the 
length in nucleotides as those of the next-largest non-segmented 
RNA virus.59 The bioinformatics prediction of a putative exori-
bonuclease (ExoN) encoded in replicase nonstructural protein 14 
(nsp14) of all CoVs led to the speculation that ExoN functions 
in proofreading during replication and that acquisition of ExoN 
by a precursor virus was critical for expansion and maintenance 
of the large RNA genomes of CoVs.55 The amino-terminal half 
of the 59-kDa nsp14 includes 3'-to-5' ExoN motifs I (DE), II 
(D) and III (D), which were originally identified in cellular 
enzymes of the DEDD superfamily, including those that cata-
lyze DNA proofreading.55,61,62 Bacterially expressed SARS-CoV 
nsp14 has been shown to have 3'-to-5' ExoN activity in vitro, 
and alanine substitution of the DE-D-D residues profoundly 
impairs or abolishes this activity.48 The intracellular RNA tar-
gets for ExoN activity likely include viral RNA intermediates; 
importantly, however, they may also include cellular mRNAs, 
noncoding RNAs and/or microRNAs, which encode or regu-
late critical antiviral activities during infection.63 Studies from 
our laboratories also indicated that the carboxy-terminal half of 
nsp14 has independent functions in RNA synthesis and virulence 
in animals,64,65 a conclusion which was confirmed by the demon-
stration that the carboxy-terminal half of nsp14 encodes a novel 
cap N7-methyltransferase function.49 Proteomic studies, while 
controversial, indicate robust two-way interactions between 
nsp14, nsp8 and ORF9b or nsp14 and nsp10; the latter study also 
Figure 3. Mutations detected in SArS-Cov and S-exoN Mutants. (A) SArS-Cov genome with nsp14-exoN in yellow and diamond indication location of 
exoN mutant. (B) Mutations identified in 10 SArS-Cov plaque clones (~320 knt). Legend above indicates type of mutations. (C) Mutations identified in 
10 S-exoN plaque clones (~320 knt). (D) representative S-exoN plaque clones showing unique and shared mutations and patterns. (e) Spike glyco-
protein showing the schematic of spike subunits and domains. Lower schematic shows unique mutations across spike from 10 S-exoN plaque clones 
(upright-blue) and from population Solexa Sequencing (inverted-black).
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eukaryotic RNA pol II and bacterial RNAP.70 (3) Nsp14 could 
increase RdRp fidelity through an allosteric effect, transmitting 
conformational changes through the RdRp. Although a precedent 
of this situation in DNA or RNA proofreading is not obvious, 
there are numerous examples of cofactor-enzyme allostery. (4) 
Nsp14 ExoN could participate in repair by RNA recombination. 
Considering that high-frequency homologous recombination in 
the form of discontinuous transcription is central to nidovirus 
gene expression, and that ExoN mutants of human CoV-229E 
have altered subgenomic mRNA ratios and aberrant mobilities,48 
it is reasonable to propose that subgenomic transcriptional and 
recombination repair may have evolved in CoVs and that nsp14-
ExoN is required for this process. A most likely model is that 
nsp14 cooperates with other CoV enzymes to form a complex 
that is involved in error recognition and repair. Although nsp14 
alone has been shown so far only to hydrolyze nucleotides at the 3' 
terminus of RNA, sequential action of nsp15-EndoU and nsp14-
ExoN would theoretically allow removal of internal, mismatched 
nucleotides. Thus, whereas nsp14 can facilitate correction of resi-
dues at only the growing end of a nascent RNA chain, coopera-
tive interaction of nsp15 and nsp14 could facilitate correction of 
residues at other sites, and conceivably in full-length molecules 
that are no longer nascent. Finally, CoVs encode methyltransfer-
ase (nsp16) that interacts specifically with nsp14 for cap meth-
ylation and which could also be participating in fidelity or other 
RNA modifications that allow expansion of the CoV genome.57
Limits of Replication Fidelity and Mutational 
Diversity in RNA Viruses
The potential for genetic variability of RNA viruses has long been 
considered to be fundamental to their evolution, adaptation and 
escape from host responses. However, the effects of changes in 
replication fidelity, susceptibility to accumulation of deleterious 
mutations and lethal mutagenesis are not well studied for many 
viruses. Genetic determinants including size of genome and pres-
ence of repair mechanisms such as proofreading, replicase fidelity 
and recombination, as well as other as yet undetermined factors 
may have evolved quite differently in distinct virus families. 
The high mutation rates of RNA viruses also render them par-
ticularly susceptible to repeated genetic bottleneck events during 
replication, transmission between hosts or spread within a host, 
resulting in progressive deviation from the consensus sequence 
associated with decreased viral fitness and sometimes extinc-
tion.15,71,72 The process by which populations of asexual organ-
isms tend to accumulate deleterious mutations in the absence of 
recombination is referred to as Muller’s ratchet.73 Muller’s ratchet 
has been shown to be applicable to multiple RNA viruses dur-
ing plaque-to-plaque passage74-78 and to result in accumulation 
of mutations and lethal mutagenesis and extinction of plaque-
passaged viruses. For example, some FMDV clones are suscep-
tible to genetic bottleneck-mediated extinction, while others are 
resistant.77 Mutagenesis has also been proposed to work as an 
antiviral strategy.9,79 A major mechanism of action of ribavirin 
and other RNA mutagens is lethal mutagenesis, as demonstrated 
with poliovirus,16,80,81 and other RNA viruses, including HIV, 
sequencing (Sanger) of 10 wt and 10 S-ExoN plaque isolates from 
a single round of infection. The results showed a 21-fold increase 
in mutational frequency and 14-fold increase in mutation rate 
across the S-ExoN genomes compared with wt SARS-CoV. For 
both S-ExoN and M-ExoN, mutations were distributed across 
the genomes with no statistical bias for regions of the genome, 
for type of mutation (codon position, transversion, transition) 
or for synonymous, non-synonymous or non-coding mutations. 
The analysis was only performed on viable replication-competent 
populations or plaques, and therefore excluded lethal or pro-
foundly deleterious individual or combination mutations. Thus, 
the results likely highly under-represent the numbers, types and 
locations of mutations that would be detected in analysis of total 
viral genomes from a round of replication that would include 
both non-viable or minor mutations and defective interfering 
genomes. When the mutation patterns in the genomes from each 
of the 10 plaque isolates of S-ExoN were compared, 100 muta-
tions were identified, and both the individual mutations and 
the “mutation sets” for each genome were unique. Finally, the 
growth of multiple plaque isolates showed that all plaque isolates 
had growth patterns with defects compared to wt SARS-CoV but 
indistinguishable from the initial recovered S-ExoN population 
or from each other.
ExoN: An RNA-dependent RNA Proofreading 
Machine?
The results from both M-ExoN and S-ExoN mutants, as well as 
the in vitro ssRNA exonuclease activity of SARS-CoV nsp14, all 
argue strongly that nsp14-ExoN directly mediates or participates 
in the prevention or repair of mutations, which would constitute 
RNA proofreading, an enzymatic activity not previously reported 
during the replication of RNA viruses. A nuclease activity of 
influenza virions in removing non-cognate residues from the 3' 
termini of capped primers was reported as evidence of proofread-
ing, but this was not tested during replication and has not been 
further investigated or confirmed by other labs.68 Rather, others 
have tested for and failed to find evidence for 3' to 5' exonucle-
ase activity or proofreading in RNA viruses,69 and have generally 
concluded that the energy and fitness cost exceeded the need for 
error recognition or repair mechanisms. Thus it may be that the 
incorporation of nsp14 ExoN in the coronaviruses both allowed 
expansion of the genome and then was required for maintenance 
of the large and complex genome integrity. In this case the cen-
tral unanswered research question remains: by what mechanism 
does nsp14 increase fidelity? There are several possible models, 
each of which would be unprecedented among RNA viruses, 
and which could occur alone or in combination as functions of 
nsp14 or with other replicase proteins. (1) Nsp14 ExoN could 
directly mediate RNA proofreading. This would be analogous to 
DNA proofreading where the exonuclease activity is oftentimes 
provided by a subunit distinct from the polymerase activity. In 
this regard it is notable that DNA proofreading exonucleases also 
belong to the DE-D-D superfamily. (2) Nsp14 could stimulate an 
intrinsic putative 3'-to-5' ExoN activity of the RdRp. This would 
be similar to RNA proofreading during cellular transcription by 
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demonstrated that in population passage with selection limited 
only to growth at 18 h, massive diversity in the population was 
tolerated and still allowed adaptation for increased growth. The 
effect of more stringent genetic bottleneck (Muller’s Ratchet) 
was tested using MHV-ExoN, in which plaque-to-plaque passage 
of 10 plaques each of wt MHV and M-ExoN was performed in 
parallel (Fig. 4). Ten clones each of WT-MHV-A59 and MHV-
ExoN were subjected to ten serial plaque-to-plaque transfers in 
murine DBT cells. Two M-ExoN1 clones became non-recover-
able during this passage series (one at p4 and one at p8), whereas 
all MHV clones were recoverable throughout. Moreover, titers 
from M-ExoN plaque passage showed a trend of decreasing aver-
age titer over passage, whereas the titer from WT-MHV remained 
constant. The results suggest that ExoN mutator viruses may 
be more susceptible to accumulation of deleterious mutations 
driven by repeated population bottlenecks. Conversely, it was 
surprising that the plaque passage revealed no rapid extinction 
of the mutant, suggesting that other mechanisms have evolved 
to stabilize populations and prevent lethal mutagenesis, and/or 
that CoVs tolerate the accumulation of massive mutational loads 
across the expanded genomes. Comparison of complete genome 
sequences of extended plaque and population passages will be 
required to test these possibilities.
Applications
The genomes of positive-strand RNA viruses have consider-
able capacity to evolve quickly in response to changing ecologic 
conditions and/or host environments. Mutation rate is a criti-
cal parameter for understanding virus evolution, and restric-
tion in genetic diversity within a population of viruses leads to 
lower adaptability and pathogenicity. Moreover, a general trend 
toward an inverse correlation between genome size and replica-
tion fidelity has been demonstrated by high variations in RdRp 
error rates that range from about 10-4 to 10-6.89 Based primarily 
on studies with enteroviruses, RNA viruses with smaller genome 
sizes seem to regulate replication fidelity by a long distance net-
work of dynamic interactions throughout the 3Dpol RdRp that 
function to regulate RNA binding and recognition, ligand rec-
ognition and binding, protein conformation and RNA synthe-
sis.90 Fidelity can be further modified by virus-host interactions 
that regulate RNA replicase fidelity or RNA recombination and 
repair. In contrast to other positive strand RNA viruses, CoVs 
appear to have expanded replicase fidelity by acquiring and evolv-
ing a unique enzymatic activity, encoded with the ExoN nsp14 
replicase protein.7,8 Clearly, the existing paradigm of a lumber-
ing error-prone RdRp will be replaced with one that recognizes 
a more complex, highly tuned and regulated protein machine 
that was likely essential for the expansion of the CoV genome. 
There is a critical need to elucidate the molecular mechanisms 
governing ExoN fidelity regulation, and we are in the process 
of designing in vitro ExoN mutant assays. Nonetheless, the 
existence of a non-essential exogenous activity which appears 
to modify CoV RdRp fidelity provides novel opportunities for 
experimental testing of the fundamental relationships between 
fidelity and replication, recombination, adaptation, cross species 
FMDV, LCMV and Hantaan virus.82-85 In contrast, SARS-CoV 
is highly resistant to ribavirin in vitro and in vivo;86,87 in fact, in 
some instances, the drug exacerbates in vivo disease.88
Impact of ExoN Mutator Phenotype on CoV Genome 
Diversity and Stability
The susceptibility to varying degrees of genetic bottleneck has 
been addressed for the M-ExoN and S-ExoN mutator viruses 
in comparison with wt parental cloned strains. SARS-CoV and 
S-ExoN were passaged as populations (three independent pas-
sages each) at fixed intervals (18 h) and with titer determination 
and equivalent MOI for passage 20 times (Fig. 4). Interestingly, 
both SARS-CoV and S-ExoN had similar responses, with selec-
tion for increased titer (1–2 log) by passage 10, after which adap-
tation reached a plateau. Analysis of sequence showed retention 
of the ExoN mutations at passage 10, indicating that a primary 
revertant was not the cause of increased growth. Further, up to 
passage 10 the total mutational diversity of the S-ExoN popula-
tions dramatically exceeded that of wt SARS-CoV. These results 
Figure 4. Population and plaque passage of S-exoN and M-exoN. 
(A) Population passage of wT SArS-Cov and S-exoN (Adapted from 
eckerle, et al.7). (B) Parallel plaque passages of 10 plaques each of wT-
MHv and M-exoN. *indicates passage where loss of a plaque lineage 
occurred.
©2011 Landes Bioscience.
Do not distribute.
276 rNA Biology volume 8 issue 2
Experimental Evolution
Of the 335 new emerging infectious diseases that were identi-
fied between 1940–2004, 60.3 percent were zoonoses, 71.8 per-
cent of which originated in wildlife.93 As pathogen emergence 
has also been increasing overtime, coupled with greater rates of 
global dissemination,93 the threat to global health and economies 
is profound. Strategies that can identify viral threats that emerge 
as a consequence of advantageous mutations in response to select 
evolutionary pressure(s) would provide profound advances in the 
ability of the Global Health Response Network to control emerg-
ing diseases. The existence of a defined ExoN-mediated muta-
tor phenotype may allow for mechanistic insights and modeling 
of the mutation repertoires that govern: (a) the rapid selection 
of host range expanded mutant viruses which represent precur-
sors to future epidemic emergences; (b) pathways of escape from 
therapeutic human monoclonal antibodies and drugs; (c) limits 
of genome variation and stability; and (d) replicase mutations 
and interacting networks which restore fidelity in passaged ExoN 
mutant viruses. For example, CoV phylogeny is punctuated by 
numerous shifts between host species and cross-species trans-
mission is readily achieved in co-cultures and during persistent 
infections in vitro.1,94,95 In nature, human coronavirus (HCoV) 
OC43 emerged around 1,900 from closely related bovine CoVs, 
whereas HCoV 229E likely emerged from closely related group 
1 bat coronaviruses around 1,800 in Africa,96,97 leading some to 
propose that nearly all human and animal CoVs originated from 
a vast reservoir of strains circulating in bat species.6,98 SARS-CoV 
is also a zoonotic virus that crossed the species barrier, most likely 
originating from bats, following amplification in other species 
(civet cats, raccoon dogs), prior to transmission to humans.2,3,99 
Our group has used synthetic biology to reconstruct full-length 
genomes of SARS-like bat CoV precursors to the 2002–2003 
epidemic strains.5,100,101 Although these strains replicate but do 
not spread because they lack the appropriate receptor-binding 
domain, recombinant bat coronaviruses harboring the SARS-
CoV receptor binding domain (RBD) replicate efficiently and 
use angiotensin 1 converting enzyme 2 (ACE2) as a receptor for 
docking and entry. These data suggest that the trimeric spike gly-
coprotein of CoVs may be plastic and modular in design, readily 
allowing for protein domains to be exchanged between divergent 
S glycoproteins from different strains.32 We propose that blend-
ing the ExoN mutator phenotype into synthetically reconstructed 
zoonotic viruses provides a strategy to rapidly identify pathway 
components and mutation sets that govern trans-species move-
ment in cell or organ cultures and in vivo. We hypothesize that 
the CoV ExoN mutator phenotype constitutes a robust investiga-
tive platform to predict mutations and possibly recombinants in 
advance of their occurrence by identifying advantageous muta-
tions governing host range and virus cross-species transmission.
Pathogenesis
Genetic diversity within a quasispecies has been proposed to 
contribute to pathogenesis by cooperative interactions among 
engineered variant viruses within a population.12,17 However, the 
transmission, genome evolution and pathogenesis while simul-
taneously providing new avenues for therapeutic enhancement 
of lethal mutagenesis and the rational design of live attenuated 
vaccines.91,92 Historically, the extent of genetic diversity in RNA 
virus populations has most often been analyzed by sequencing 
a small number of genomes at low coverage or a small region at 
high coverage. The former approach lacks resolution while the 
latter is narrowly focused, so extrapolation to the entire genome 
can be misleading. Deep sequencing approaches like mRNA-
seq provide new opportunities for high resolution mapping of 
mutation distributions across genomes.7
Genome Evolution
The availability of mutator phenotype mutants of both MHV 
and SARS that can tolerate up to 20-fold increase in mutation 
rate, accumulate massive mutational diversity at the population 
level and survive extended population and plaque passage, rep-
resents a powerful tool to directly test long-standing questions 
concerning the role of diversity and fidelity in virus replication, 
pathogenesis and evolution. How do CoVs maintain a large and 
complex genome over time while allowing sufficient mutation 
rates for adaptation and trans-species movement? Is the fidelity of 
wt CoV replication fixed by highly selected interactions between 
the RdRp, ExoN and possibly other viral and cellular proteins or 
is it flexible in response to altered environmental conditions as has 
been shown for bacteria such as E. coli? What are the limitations 
to CoV genome diversity in vitro and in vivo? Does the ExoN 
mutator phenotype result in more rapid adaptation or attenua-
tion associated with lethal mutational load and rapid extinction 
during infection in vivo? Does the mutator phenotype increase 
susceptibility to mutagens for lethal mutagenesis? Clearly, CoVs 
provide a rich empirical platform to address these interesting and 
unique questions in virus evolution and adaptation.
Replication and Recombination
CoVs use a unique discontinuous mechanism to transcribe a 
series of progressively larger subgenomic mRNAs, and each con-
tains a leader RNA sequence that is derived from the 5' end of 
the genome. RNA recombination and coronavirus subgenomic 
transcription occur by template switching mechanisms, which 
can occur either by sequence-assisted base pairing and hydro-
gen bonding networks or sequence independent processes in 
mismatched regions. Given the potential need to appropriately 
process and match the 3' ends of nascent RNAs and their tem-
plates, the ExoN mutator phenotype provides a novel approach 
to investigate the role of fidelity in regulating both full length 
and subgenomic length RNA synthesis, transcription attenuation 
during negative strand RNA synthesis and as potential regula-
tors of RNA recombination distributions and frequencies across 
the genome. The possibility that ExoN interacts with other RNA 
modifying enzymes such as nsp15 EndoU and nsp16 2'-O-MTase 
or interact with putative RNA processivity components encoded 
in nsp7 and 8 to modify RNA repair rates or recombination fre-
quencies may serve as a rich environment for future research.
©2011 Landes Bioscience.
Do not distribute.
www.landesbioscience.com rNA Biology 277
whereas a two- to six-fold increase in mutation frequency was suf-
ficient to cause lethal mutagenesis of poliovirus in cell culture.7,8,16 
Moreover, ribavirin is clearly ineffective against mouse-adapted 
SARS-CoV and appears to exacerbate disease, suggesting that 
the ExoN activity in wildtype viruses may reduce the efficacy of 
this important antiviral.88 The high conservation of nsp14 ExoN 
sequences among CoVs and lack of close orthologs in cells suggests 
that nsp14 ExoN might represent a promising target for design and 
development of antiviral drugs and raises the possibility that a sin-
gle drug targeting ExoN might be effective against multiple coro-
naviruses, including potential zoonotic SARS-CoV-like viruses 
from bats that emerge in the future. However, given numerous 
examples of viruses evolving drug resistance, an ExoN-targeted 
companion drug in a combination therapy would not only attenu-
ate pathogenesis by altering error rates, but also prevent reversion 
from other compounds in the cocktail. Investigating the potential 
of ExoN targeted mutations as a universal strategy to construct 
live attenuated, reversion proof CoV vaccines and antivirals seems 
broadly relevant. Studies investigating the pathogenesis of ExoN 
mutants in animal models, along with their tenability as vaccine 
candidates, are currently in progress.
Summary
The identification of a stable mutator phenotype and possible 
dedicated RNA-dependent RNA-proofreading complex is sig-
nificant for several reasons. The availability of the M-ExoN and 
S-ExoN mutant viruses constitutes a unique system to directly 
study the impact of profoundly decreased replication fidel-
ity and increased diversity on replication and pathogenesis of 
RNA viruses. The use of both traditional di-deoxy (Sanger) and 
ultradeep (Solexa) sequencing in conjunction with virus passage 
and persistent infection will allow establishment of new mod-
els for understanding the range and limitations on diversity and 
mutational load and will aid in developing tool sets for evaluat-
ing, comparing and annotating sequence diversity across RNA 
virus genomes. Massive sequence annotation and analysis during 
different stages of acute infection (intracellular, virion), as well 
as over time (passage, persistent infection) will allow mapping 
of genetic regions highly tolerant or resistant to change and to 
define potential epistatic interaction networks not predictable by 
other approaches as well as conserved across the Coronaviridae. 
Passage and sequencing of ExoN mutator viruses also will pro-
vide a system to rapidly generate extensive libraries of individual 
mutations and complete mutation sets across the genome that can 
be tested in individual coding or regulatory domains for effects 
on immune response, host range and virulence. Such studies of 
ExoN-generated decreased fidelity and increased diversity also 
represent two potentially broadly applicable strategies for live 
vaccine design that simultaneously attenuate and prevent rever-
sion to virulence. Finally, the mutator viruses and studies of 
ExoN mutant revertants will result in important insights into the 
evolutionary mechanisms by which the Nidovirales acquired (or 
lost) the capacity for RNA proofreading, and will allow testing 
of the limitations of size and complexity of RNA as a replicating 
molecule. As such, ExoN should be considered as a high impact 
impact of reduced replication fidelity on pathogenesis remains 
largely untested for RNA viruses. The CoV ExoN mutator phe-
notype represents a unique property with unclear consequences 
for adaptation and pathogenesis in animals. Although increased 
fidelity attenuates virulence of poliovirus and restricts tissue tro-
pism, the ExoN mutator activity might increase virus virulence 
and tissue tropism because of the increased population diversity 
and spread into novel tissues. Alternatively, ExoN decreased fidel-
ity might attenuate virulence because the mutation frequency may 
approach error catastrophe and drive self-annihilation of S-ExoN 
in vivo. The growth defects observed in culture seem to support 
the prediction that S-ExoN will be attenuated in animals, but these 
impairments could be trumped by potential enhanced adaptabil-
ity of S-ExoN. To assess these possibilities, pathogenesis studies in 
animal models are currently underway. Of note, a low-fidelity exo-
nuclease mutant of cytomegalovirus showed accelerated evolution 
of drug resistance in cell culture.102 Increased mutation rates in the 
GII.4 noroviruses have been proposed to account for their epochal 
evolution, increased diversity and the striking increase in the fre-
quency of human epidemics in winter.103,104 Thus, fidelity regula-
tion is a broadly relevant topic with far-ranging appeal in RNA 
virus evolution and pathogenesis. Importantly, ExoN represents 
an important and unique high impact target for understanding 
CoV replication fidelity, quasispecies diversity and pathogenesis 
and is strongly coupled with the potential of developing universal 
strategies to build safe live attenuated CoV vaccines.
Vaccines and Therapeutics
Live attenuated vaccines elicit strong protective immune responses 
with low risk of disease, leading to robust tools that protect the 
public health against pathogens like measles, poliovirus, mumps, 
smallpox, herpesviruses and rubella. Safety concerns clearly exist 
as evidenced by vaccine reversion to virulence and the develop-
ment of serious and lethal disease in a low percentage of vaccinees. 
The present regulatory environment in the US is now limiting live 
attenuated virus vaccine use because of safety concerns, attesting to 
the need for rational approaches that prevent reversion to virulence. 
The high conservation of nsp14 ExoN sequences among CoVs and 
lack of close orthologs in cells suggests that nsp14 ExoN may be a 
promising target for live attenuated virus design or antiviral thera-
peutics. Clearly, studying the ExoN mutator phenotype in patho-
genesis and as a rational approach to develop reversion-resistant 
live attenuated vaccines provides a potential rapid response strategy 
to control future emerging CoV diseases in human and domesti-
cated animals. Current treatment regimens for SARS-CoV include 
ribavirin, a nucleoside analog that induces lethal mutagenesis of 
other RNA viruses such as poliovirus, foot and mouth disease 
virus, hepatitis C virus among others.16,81,105,106 However, its pre-
cise mechanism of action against CoVs has not been determined 
and the high replication fidelity of WT MHV and SARS-CoV 
in cell culture suggests that drug-induced viral extinction thera-
pies employed against other RNA viruses might not be as effective 
against CoVs.7,8 A possible recalcitrance of CoVs to RNA mutagens 
is also suggested by our demonstration that at least in cell culture 
SARS-CoV tolerates a 16.5-fold increase in substitution frequency, 
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